hVIVO Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

hVIVO ist ein dividendenzahlendes Unternehmen mit einer aktuellen Rendite von 0.73%.

Wichtige Informationen

0.7%

Dividendenausschüttung

Ausschüttungsquote

Durchschnittlicher Branchenertrag	0.7%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	UK£0.024
Erwartete Dividendenrendite in 3 Jahren	1.2%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

hVIVO plc's (LON:HVO) Intrinsic Value Is Potentially 28% Above Its Share Price

Jan 26

Improved Revenues Required Before hVIVO plc (LON:HVO) Stock's 26% Jump Looks Justified

Jan 03

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: HVO zahlt keine nennenswerte Dividende für den Markt UK, daher muss nicht geprüft werden, ob die Zahlungen stabil sind.

Wachsende Dividende: HVO zahlt keine nennenswerte Dividende für den Markt UK, daher ist es nicht notwendig zu prüfen, ob die Zahlungen steigen.

Dividendenrendite im Vergleich zum Markt

hVIVO Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von HVO im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (HVO)	0.7%
Untere 25 % des Marktes (GB)	2.1%
Markt Top 25 % (GB)	5.7%
Branchendurchschnitt (Life Sciences)	0.7%
Analystenprognose in 3 Jahren (HVO)	1.2%

Bemerkenswerte Dividende: HVODie Dividende des Unternehmens (0.74%) ist im Vergleich zu den unteren 25 % der Dividendenzahler auf dem Markt UK (2.06%) nicht bemerkenswert.

Hohe Dividende: HVODie Dividende des Unternehmens (0.73%) ist im Vergleich zu den besten 25% der Dividendenzahler auf dem Markt UK (5.66%) niedrig.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: HVO zahlt keine nennenswerte Dividende für den Markt UK.

Barausschüttung an die Aktionäre

Cashflow-Deckung: HVO zahlt keine nennenswerte Dividende für den Markt UK.

hVIVO Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

hVIVO plc, Annual General Meeting, May 13, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

hVIVO plc to Report Fiscal Year 2023 Results on Apr 09, 2024

New minor risk - Share price stability

hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.

hVIVO plc's (LON:HVO) Intrinsic Value Is Potentially 28% Above Its Share Price

Improved Revenues Required Before hVIVO plc (LON:HVO) Stock's 26% Jump Looks Justified

hVIVO plc Signs £6.3 Million Human Challenge Study Model

At UK£0.20, Is hVIVO plc (LON:HVO) Worth Looking At Closely?

hVIVO plc Increases Revenue Guidance for 2023

hVIVO plc to Report First Half, 2023 Results on Sep 12, 2023

hVIVO plc to Develop Human Metapneumovirus Challenge Model

A Piece Of The Puzzle Missing From hVIVO plc's (LON:HVO) Share Price

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2023

A Look At The Intrinsic Value Of hVIVO plc (LON:HVO)

hVIVO plc Provides Earnings Guidance for the Full Year 2022

Forecast breakeven date pushed back to 2023

Now 22% undervalued

hVIVO plc Announces Publication of Imutex Phase I Data

Should You Investigate hVIVO plc (LON:HVO) At UK£0.11?

Less than half of directors are independent

Open Orphan plc Announces Chief Financial Officer Changes

Open Orphan plc Announces Positive Data from Peer-Reviewed Study Evaluating the in Vitro Efficacy of Flu-V

Is There An Opportunity With Open Orphan Plc's (LON:ORPH) 41% Undervaluation?

First half 2022 earnings released: EPS: UK£0 (vs UK£0.002 in 1H 2021)

Open Orphan plc Reiterates Revenue Guidance for the Full Year of 2022

Open Orphan Plc to Report First Half, 2022 Results on Sep 08, 2022

Open Orphan plc, Annual General Meeting, Jul 05, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Open Orphan plc Appoints Martin Gouldstone as Independent Non-Executive Director

Are Investors Undervaluing Open Orphan plc (LON:ORPH) By 44%?

Open Orphan plc to Report Fiscal Year 2021 Results on Jun 07, 2022

Forecast breakeven date pushed back to 2022

Less than half of directors are independent

Open Orphan plc Announces Characterisation Study Results in Nature Medicine

Open Orphan plc Appoints Yamin 'Mo' Khan as Chief Executive Officer

First half 2021 earnings released: EPS UK£0.002 (vs UK£0.012 loss in 1H 2020)

Executive Chairman recently bought UK£300k worth of stock

Open Orphan plc Announces Ethics Approval for Covid-19 Human Challenge Study

Introducing Open Orphan (LON:ORPH), The Stock That Soared 388% In The Last Year

New 90-day high: UK£0.28

Open Orphan Plc's Subsidiary Venn Life Sciences Announces Contract Extension with Carna Biosciences

Open Orphan plc Announces Contract Renewal with Top-3 Pharmaceutical Client Extending Its Consultancy Services to End of December 2021

How Much Of Open Orphan plc (LON:ORPH) Do Insiders Own?

Open Orphan plc Announces Board Changes, Effective on December 31, 2020

Calculating The Fair Value Of Open Orphan plc (LON:ORPH)

Open Orphan plc Announces the Signs of A £2.5 Million Contract by hVIVO

Analysts lower EPS estimates to -UK£0.021

New 90-day high: UK£0.20

Open Orphan plc Announces £4.3 Million Contract to Conduct Human Viral Challenge Study

Open Orphan plc to Report First Half, 2020 Results on Sep 30, 2020

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen